⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KAPA News
Kairos Pharma, Ltd.
Form 8-K
sec.gov
KAPA
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
businesswire.com
KAPA
カイロス・ファーマ（Kairos Pharma, Ltd.）、Celyn Therapeuticsから臨床段階の腫瘍領域資産2件を戦略的に取得するタームシート締結を発表
businesswire.com
KAPA
Kairos Pharma, Ltd.宣布签署战略资产收购条款清单 拟收购Celyn Therapeutics两项临床阶段肿瘤资产
businesswire.com
KAPA
Kairos Pharma, Ltd.宣布簽署投資條件書，戰略性收購Celyn Therapeutics旗下兩份臨床腫瘤資產
businesswire.com
KAPA
Kairos Pharma, Ltd.宣布簽署投資條件書，戰略性收購Celyn Therapeutics旗下兩份臨床腫瘤資產
businesswire.com
KAPA
Kairos Pharma, Ltd. annuncia la sigla di un memorandum d'intesa per l'acquisizione di due asset clinici oncologici strategici da Celyn Therapeutics
businesswire.com
KAPA
Kairos Pharma, Ltd. kondigt ondertekening aan van term sheet voor strategische overname van twee klinische oncologie-activa van Celyn Therapeutics
businesswire.com
KAPA
Kairos Pharma, Ltd. anuncia assinatura de termo de compromisso para a aquisição estratégica de dois ativos oncológicos clínicos da Celyn Therapeutics
businesswire.com
KAPA
Kairos Pharma, Ltd. firma un acuerdo estratégico para adquirir dos prometedores activos clínicos oncológicos de Celyn Therapeutics
businesswire.com
KAPA